Sign In
Buy CTIC
$9.09
+0 (+0%)
At Close: Sep 22, 2023
Why CTI BioPharma Stock Crushed the Market Today
06:55pm, Monday, 17'th Oct 2022
Simultaneous double thumbs-ups from a pair of pundits gave it boost.
Why CTI BioPharma Stock Withered on Wednesday
05:47pm, Wednesday, 12'th Oct 2022
Investors didn't exactly cheer the latest prognosticator move on the company's shares.
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
12:15pm, Wednesday, 17'th Aug 2022
CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since
Why CTI BioPharma Stock Got Rocked on Tuesday
06:23pm, Tuesday, 09'th Aug 2022
Woe betide any company that reports even a narrow bottom-line miss on quarterly results these days.
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
08:20pm, Monday, 08'th Aug 2022
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2022 Results - Earnings Call Transcript
08:11pm, Monday, 08'th Aug 2022
CTI BioPharma Corp. (NASDAQ:CTIC ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Adam Craig - Chief Executive Officer & President Jim Fong - Chief Commercial Officer
CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022
08:37am, Monday, 01'st Aug 2022
– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE , Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDA
CTI BioPharma: One Trick Pony Ready To Perform
11:39pm, Tuesday, 19'th Jul 2022
CTI BioPharma has finally fulfilled its long sought goal of FDA approval for its VONJO (JAK inhibitor pacritinib) in treatment of myelofibrosis. Armed with a wholesale cost of ~$19,500 month, VONJO co
CTI BioPharma: Approval Is Great, Now There's The Follow Through
01:46pm, Tuesday, 19'th Jul 2022
CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi.
Why CTI BioPharma Stock Blasted 18% Higher Today
06:21pm, Thursday, 07'th Jul 2022
An analyst launches coverage of the company with an unequivocal buy recommendation.
CTI BioPharma to Present at Upcoming June Conferences
04:05pm, Thursday, 02'nd Jun 2022
SEATTLE , June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City. Prese
Why CTI Biopharma Stock Is Surging Today
04:19pm, Friday, 13'th May 2022 The Motley Fool
A strong launch for the company's first commercialized drug drew a cheer from investors.
Why CTI Biopharma Stock Is Surging Today
12:19pm, Friday, 13'th May 2022
A strong launch for the company's first commercialized drug drew a cheer from investors.
CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates
09:45pm, Thursday, 12'th May 2022 Zacks Investment Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2022 Results - Earnings Call Transcript
07:25pm, Thursday, 12'th May 2022
CTI BioPharma Corp. (NASDAQ:CTIC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adam Craig - CEO and President of CTI BioPharma James Fong - SVP and Chief Commercial O
